{
    "clinical_study": {
        "@rank": "100867", 
        "arm_group": [
            {
                "arm_group_label": "group A: DSW group", 
                "arm_group_type": "Experimental", 
                "description": "ingesting DSW 200 cc four times a day (one hour before meal and bed time);"
            }, 
            {
                "arm_group_label": "group B: non-DSW group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time)."
            }
        ], 
        "brief_summary": {
            "textblock": "Deep sea water (DSW) is characterized by high purity, low temperature, high nutrients and\n      minerals and is obtained from the water flows 200 meters under the surface of the sea. The\n      inhibition of H. pylori growth by DSW has been demonstrated in vitro study. However, up to\n      now, there is few randomized control study to evaluate the anti-bacterial effects of\n      ingesting DSW in patients with H. pylori infection.\n\n      The aims of this study are:\n\n        1. to evaluate the anti-bacterial effects of ingesting DSW in patients with H. pylori\n           infection;\n\n        2. to evaluate the patient adherence and adverse effects of ingesting DSW."
        }, 
        "brief_title": "Anti-H. Pylori Effect of Deep See Water", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Helicobacter Pylori Infection", 
        "condition_browse": {
            "mesh_term": "Helicobacter Infections"
        }, 
        "detailed_description": {
            "textblock": "Patients having H. pylori-positive chronic gastritis with/without small erosions or peptic\n      ulcer scars will be recruited. Before treatment, H. pylori infection status will be examined\n      by endoscopy with biopsy or 13C-urea breath test (13C-UBT). All patients will receive\n      13C-UBT before treatment, at the end of 2 week's treatment and 4 weeks after termination of\n      treatment. A computed generated random numbers sequence will be blocked (2:1; block sizes of\n      six) into two groups, say A and B.\n\n      group A - ingesting DSW 200 cc four times a day (one hour before meal and bed time); group B\n      - ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed\n      time).\n\n      To keep the study in double-blind model, the picture of package for DSW and non-DSW drinking\n      water will be the same.\n\n      Prokinetics (metoclopramide 5 mg/tab 1 tid) and antacid (strocain tablet (oxethazaine 5 mg\n      and polymigel 244 mg/tab) 1 tid) will be permitted for relieving the dyspeptic symptoms.\n\n      All patients will be asked to complete a questionnaire and to record symptoms and water/drug\n      consumption daily during the treatment period. Post-treatment, the patients will be seen at\n      the Outpatients Clinic to investigate patient adherence and adverse of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients having H. pylori-positive chronic gastritis with/without small erosions or\n             peptic ulcer scars who are aged greater than 20 years and are willing to received\n             anti-H. pylori treatment.\n\n        Exclusion Criteria:\n\n          -  pregnant or nursing woman\n\n          -  serious concomitant illness and malignant tumor of any kind\n\n          -  serious bleeding from gastrointestinal tract\n\n          -  previous gastric surgery\n\n          -  receiving bismuth salts, Proton pump inhibitors, or antibiotics in the previous\n             month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933659", 
            "org_study_id": "201304065RIND"
        }, 
        "intervention": {
            "arm_group_label": "group A: DSW group", 
            "description": "ingesting DSW 200 cc four times a day (one hour before meal and bed time)", 
            "intervention_name": "DSW", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Helicobacter pylori", 
            "deep see water"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "10002"
                }, 
                "name": "National Taiwan University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Anti-bacterial Effects of Ingesting Deep Sea Water in Subjects With H. Pylori Infection", 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Jyh-Chin Yang, M.D.Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The eradication rates (efficacy) will be evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis.", 
            "measure": "to compare the efficacy of DSW and non-DSW drinking water as anti-H. pylori regimen", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933659"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The safety and patient adherence will be evaluated by the number of participant with adverse events and by counting unused medication after the treatment.", 
            "measure": "to compare the adverse effects and patient adherence of DSW and non-DSW drinking water as anti-H. pylori regimen", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}